Non-invasive assessment of vascular reactivity in forearm skin of patients with primary Raynaud's phenomenon and systemic sclerosis

British Journal of Rheumatology

Volumn 35, Issue 12, 1996, Pages 1281-1288

  Anderson, M E ^a   Hollis, S ^b   Moore, T ^a   Jayson, M I V ^a   Herrick, A L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Iontophoresis; Laser doppler; Neuroendothelial control; Primary Raynaud's phenomenon; Scleroderma; Systemic sclerosis

Indexed keywords

ACETYLCHOLINE; ADRENALIN; NITROPRUSSIDE SODIUM; VASOACTIVE AGENT;

ADULT; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOREARM; FOREARM BLOOD FLOW; HUMAN; HYPEREMIA; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; MALE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REPERFUSION; SKIN; SYSTEMIC SCLEROSIS; VASODILATATION;

ACETYLCHOLINE; ADULT; EPINEPHRINE; FEMALE; FOREARM; HUMANS; IONTOPHORESIS; MALE; MIDDLE AGED; NITROPRUSSIDE; RAYNAUD DISEASE; REGIONAL BLOOD FLOW; REPRODUCIBILITY OF RESULTS; SCLERODERMA, SYSTEMIC; SKIN; VASOCONSTRICTOR AGENTS; VASODILATOR AGENTS;

EID: 0030453947     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Dowd PM, Goldsmith PC, Bull HA, Burnstock G, Foreman JC, Marshall I. Raynaud's phenomenon. Lancet 1995;346:283-90.
2. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: a vascular hypothesis. Semin Arthritis Rheum 1975;4:351-68.
3. Sloan JB, Soltani K. Iontophoresis in dermatology. J Am Acad Dermatol 1986;15:671-84.
4. Prescott RJ, Freemont AJ, Jones CJP, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol 1992;166:255-63.
5. LeRoy EC, Medsger TA. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol 1992;10:485-8.
6. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-90.
7. Westerman RA, Widdop RE, Hannaford J et al. Laser Doppler velocimetry in the measurement of neurovascular function. Aust Phys Eng Sci Med 1988;11:53-66.
8. Khan F, Hoffman J. Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon. Circulation 1994;89:1183-8.
9. Wigley FM, Wise RA, Mikdashi J, Schaefer S, Spence RJ. The post-occlusive hyperemic response in patients with systemic sclerosis. Arthritis Rheum 1990;33:1620-5.
10. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002-12.
11. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980;288:373-6.
12. Agostoni A, Marasini B, Biondi ML et al. L-arginine therapy in Raynaud's phenomenon? Int J Clin Lab Res 1991;21:202-3.
13. Lindblad LE, Ekenvall L, Etzell B, Bevegard S. Adrenoceptors in Raynaud's disease. J Cardiovasc Pharmacol 1989;16:881-5.
14. Westerman RA, Lindblad LE, Wajnblum D, Roberts RGD, Delaney CA. Confounding factors in non-invasive tests of neurovascular function in diabetes mellitus. Clin Exp Neurol 1992;29:149-60.
15. Freedman RR, Sabharwal SC, Desai N, Wenig P, Mayes M. Increased alpha-adrenergic responsiveness in idiopathic Raynaud's disease. Arthritis Rheum 1989;32:61-5.
16. Bedarida GV, Kim D, Blaschke TF, Hoffman BB. Venodilation in Raynaud's disease. Lancet 1993;342:1451-4.
17. Burnstock G. Integration of factors controlling vascular tone. Anesthesiology 1993;79:1368-80.
18. Bunker CB, Terenghi G, Springall DR, Polak JM, Dowd PM. Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon. Lancet 1990;336:1530-3.
19. Zamora MR, O'Brien RF, Rutherford RB, Weil JV. Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 1990;336:1144-7.
20. Cimminiello C, Milani M, Uberti T, Arpaia G, Perolini S, Bonfardeci G. Endothelin, vasoconstriction, and endothelial damage in Raynaud's phenomenon. Lancet 1991;337:114-5.
21. Kahaleh MB. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Arthritis Rheum 1991;34:978-83.
22. Yamane K, Miyauchi T, Suzuki N et al. Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 1992;19:1566-71.
23. Harker CT, Ousley PJ, Harris-J, Edwards JM, Taylor LM, Porter JM. The effects of cooling on human saphenous vein reactivity to adrenergic agonists. J Vasc Surg 1990;12:45-9.
24. Kahaleh B, Matucci-Cerinic M. Raynaud's phenomenon and scleroderma. Dysregulated neuroendothelial control of vascular tone. Arthritis Rheum 1995;38:1-4.